April 10 meeting in Charlotte, NC, co-located with HMP Global’s SAWC Spring | WHS, advances regulatory science and patient-centered evidence development.
MALVERN, PA, UNITED STATES, March 4, 2026 /EINPresswire.com/ — As wound care innovation increasingly depends on stronger clinical evidence and meaningful patient input, the 2026 WCCC Driving Innovation in Wound Care Summit will convene federal regulators, clinicians, researchers, industry leaders, and patient advocates on April 10 in Charlotte, North Carolina. The exclusive working meeting emphasizes regulatory science, real-world evidence, patient-reported outcomes, and practical collaboration designed to produce concrete deliverables for the wound care community.
Co-located with HMP Global’s Symposium on Advanced Wound Care (SAWC) Spring | WHS, the Summit is structured to move beyond discussion and toward defined actions that support evidence development and patient-centered progress.
What Is the WCCC Driving Innovation in Wound Care Summit?
The WCCC Driving Innovation in Wound Care Summit is a full-day, multi-stakeholder working meeting convened by the Wound Care Collaborative Community (WCCC). The program brings together representatives from the U.S. Food and Drug Administration (FDA), clinicians, researchers, industry partners, and patients to address scientific, operational, and community priorities affecting wound care innovation.
The structure emphasizes applied discussion and practical insight rather than general policy commentary.
Federal Leadership and Regulatory Science Focus
Bleta Vuniqi, MS, BA, Acting Office Director, OHT 4, Office of Surgical and Infection Control Devices, CDRH will deliver the keynote, “Strengthening FDA–WCCC Collaboration Across the Total Product Lifecycle.”
Her address will explore collaborative strategies to accelerate wound care innovation, the role of real-world evidence in regulatory decision-making, and the FDA’s Total Product Lifecycle Advisory Program, highlighting pathways that may expedite review and market entry for breakthrough and safety-enhancing products.
Moderators are WCCC President Vickie R. Driver, DPM, MS, FACFAS, and Board Member David Alper, DPM.
Featured Sessions
• Studying the Patients We Actually Treat: The Role of Real-World Evidence
This session examines real-world evidence initiatives and recent publications emerging from WCCC. Discussion will address how emerging natural history data may influence clinical trial design and patient care decisions.
• The Power of Patient Voices and Developing Patient-Reported Outcomes (PROs)
Centered on the lived experience of patients with chronic wounds, this session focuses on incorporating patient perspectives into the development of meaningful PRO measures for clinical research. Participants include clinical leaders, patient representatives, and FDA contributors from the Patient-Focused Drug Development (PFDD) program within CDER.
• Innovation in Motion: AI, Digital Tools, and Data Readiness
This session explores how digital tools and structured data processes can strengthen trial design and improve operational readiness.
• Future by 2030: The Road to Readiness
A forward-looking dialogue examining long-term priorities for the wound care community and defining measurable milestones to guide progress toward 2030.
• State of the Union: Turning Policy into Practice: An Industry Perspective
Presented by Principal Partner Organogenesis Inc., this session examines how policy and clinical realities intersect and outlines practical steps industry can take to support collaborative progress within WCCC initiatives.
• Collaboration That Moves the Field: Industry’s Role with WCCC
Delivered by Headline Sponsor Encoll Corporation, this session examines the role of industry engagement within the WCCC and how structured cross-sector collaboration can advance innovation and strengthen evidence development efforts across the wound care landscape.
Why This Summit Matters Now
Wound care development programs increasingly need real-world data, structured patient-reported outcome measures, and coordinated scientific dialogue between regulators, clinicians, and innovators. The Summit’s working format is designed to translate discussion into defined next steps, including frameworks, publications, and community initiatives that extend beyond the meeting itself.
Attendance is limited to preserve substantive engagement and to ensure that each session produces tangible outcomes aligned with WCCC’s mission.
Industry Participation and Support
Industry engagement reflects a shared commitment to strengthening regulatory science and advancing collaborative innovation within the wound care community. Supporters include:
• Principal Partner: Organogenesis Inc.
• Headline Sponsor: Encoll Corporation
• Collaborators: MiMedx Group, Inc. and New Horizon Medical Solutions
• Supporters: BioLab Sciences, Convatec, Eluciderm, INTENT Biologics, MediWound Ltd., Moleculight, Mölnlycke, MIMOSA Diagnostics, MTF Biologics, Stability Biologics, Venture Medical, and ViaDerma Pharma
• Contributors: Altrazeal Life Sciences Inc. and Integra LifeSciences
Who Should Apply
The Summit is intended for stakeholders directly involved in wound care research, product development, clinical trial design, patient engagement initiatives, and regulatory science. This includes clinicians, clinical investigators, regulatory professionals, industry leaders, and patient advocates contributing to evidence generation and community-driven progress.
Event Details
• Event: WCCC Driving Innovation in Wound Care Summit
• Date: April 10, 2026
• Location: Charlotte, North Carolina
• Co-Located with SAWC Spring | WHS
• Learn more on the event website
• Application Form to Attend
About HMP Global
HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on LinkedIn or visit hmpglobal.com.
Sandi Beason, APR
HMP Global
pr@hmpglobal.com
Visit us on social media:
LinkedIn
Facebook
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![[Webinar] Bettersize Introduces the Bettersizer 2600 Plus for Advanced Particle Size Analysis](https://img.einnews.com/large/1073258/webinar-bettersizer-2600-plus.jpeg)
